MeiraGTx Holdings plc (MGTX) SEC Filings & Earnings Calls

No material risks identified; routine board appointment.

“Standard director appointment with no related party transactions or arrangements.”

Dependence on product candidates still in development

“We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.” · word for word

Need for additional capital

“We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.” · word for word

Regulatory uncertainty for gene therapy

“Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.” · word for word

Clinical and regulatory risks remain for both bota-vec and AAV2-hAQP1; no approved treatments yet.

“Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mid-2027.” · word for word

Obligations secured by assets; potential dilution from equity issuance and royalty payments on future sales.

“granted a security interest in the Obligors' cash, equity interests, receivables, property, plant & equipment... Revenue Payments equal to 1.95% of the global net sales”

Clinical and regulatory risk

“We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future, and may never achieve or maintain profitability.” · word for word

Financing risk

“We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.” · word for word

Debt covenant risk

“We may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements” · word for word

Shareholders' deficit risk

“Total Shareholders' Deficit $ (58,130 ) $ (5,793 )”

Clinical-stage company with no approved products or revenue; regulatory and commercial execution risk remains high.

“Pre-revenue clinical stage genetic medicines company; no revenue reported.”

Dependence on successful regulatory submissions for bota-vec and AAV2-hAQP1; any delays or failures could materially impact valuation.

“Working expeditiously to complete regulatory submissions in the U.S., EU, UK and Japan.” · word for word

Royalty obligation to J&J on bota-vec sales starting mid-2029; mid-teens royalty could pressure future margins.

“J&J is eligible to receive... a mid-teens royalty on global net sales starting in mid-2029.” · word for word

Dependence on strategic collaborations

“The Company's progress is heavily reliant on collaborations with Lilly and Hologen; any failure in these partnerships could materially impact operations.”

Clinical development risk

“The Company's product candidates are in clinical development and may fail to demonstrate safety and efficacy, leading to delays or failure to obtain regulatory approval.”

Financing risk

“The Company has a history of net losses and may need additional capital to fund operations, though recent collaborations and offerings have provided significant funding.”

Regulatory risk

“The Company's products are subject to FDA and other regulatory approvals; failure to obtain or delays in obtaining approvals could harm the business.”

Manufacturing risk

“The Company's manufacturing capabilities are critical; any disruption or failure to maintain regulatory compliance could impact supply.”

Complex multi-party agreements with potential execution risk and future funding obligations.

“Hologen shall fund the remaining portion of the Upfront Payment... Hologen will own a minority interest in MeiraGTx Manufacturing.”

Dilution to existing shareholders from 11.1M new shares.

“11,111,111 ordinary shares”

Early-stage data; regulatory and commercial success not guaranteed. Forward-looking statements highlight risks.

“These forward-looking statements are based on management’s current expectations... involve known and unknown risks, uncertainties and other important factors...”

Contingent payments and royalties may strain future cash flows if product is not successful.

“Buyer agreed to pay Seller a one-time, future contingent consideration of $50,000,000 upon both of the following milestones being achieved... aggregate net sales... first exceeds $250,000,000.”

Clinical Trial Failure Risk

“We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.” · word for word

Capital Requirement Risk

“We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.” · word for word

Regulatory Uncertainty

“Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.” · word for word

Dependence on Perceptive Credit Holdings for financing; related party transaction risk

“Ellen Hukkelhoven, a board member, is Head of Biotechnology Investments at Perceptive Advisors; affiliates own >10% of outstanding shares”

Concentrated ownership and debt from Perceptive entities; lock-up reduces near-term selling pressure

“Perceptive Master Fund and affiliates own >10% of outstanding shares; Perceptive Credit Holdings III holds $75M note”

Cash burn and going concern risk

“The Company has not yet achieved profitable operations...accumulated deficit at September 30, 2025 totaled $831.3 million...used $93.0 million in cash flows from operations” · word for word

Dependence on collaboration payments

“Company estimates that its cash and cash equivalents on-hand...together with the $75.0 million upfront payment from Eli Lilly...and the $22.0 million deposit received from Hologen...will be sufficient to cover its expenses for at least the next twelve months” · word for word

Clinical and regulatory uncertainty

“We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.” · word for word

Dependence on Lilly for development and commercialization.

“Lilly will have the right to research, develop and commercialize products under the Collaboration Agreement, at its cost.” · word for word